Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Spruce Biosciences Inc (SPRB)

Spruce Biosciences Inc (SPRB)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 85,620
  • Shares Outstanding, K 1,070
  • Annual Sales, $ 4,910 K
  • Annual Income, $ -53,040 K
  • EBIT $ -49 M
  • EBITDA $ -49 M
  • 60-Month Beta 3.45
  • Price/Sales 19.71
  • Price/Cash Flow N/A
  • Price/Book 8.43

Options Overview Details

View History
  • Implied Volatility 0.00% (unch)
  • Historical Volatility 110.52%
  • IV Percentile 0%
  • IV Rank 0.00%
  • IV High 977.78% on 01/02/25
  • IV Low 0.00% on 12/05/25
  • Expected Move (DTE 11) 0.00 (0.00%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 3
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 104
  • Open Int (30-Day) 104
  • Expected Range 93.55 to 93.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -6.52
  • Number of Estimates 1
  • High Estimate -6.52
  • Low Estimate -6.52
  • Prior Year -42.86
  • Growth Rate Est. (year over year) +84.79%

Price Performance

See More
Period Period Low Period High Performance
1-Month
74.01 +10.07%
on 12/01/25
129.00 -36.85%
on 11/10/25
-45.53 (-35.85%)
since 11/07/25
3-Month
7.26 +1,022.13%
on 09/29/25
240.00 -66.06%
on 10/07/25
+72.47 (+805.18%)
since 09/08/25
52-Week
4.28 +1,805.65%
on 04/29/25
240.00 -66.06%
on 10/07/25
+43.98 (+117.33%)
since 12/06/24

Most Recent Stories

More News
Spruce Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Updates

Granted Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) for the Treatment of Sanfillipo Syndrome Type B (MPS IIIB) Biologics...

SPRB : 80.99 (+1.25%)
Spruce Biosciences Secures $50 Million Investment Deal

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Spruce Biosciences...

SPRB : 80.99 (+1.25%)
Spruce Biosciences Announces $50.0 Million Private Placement Financing

Spruce Biosciences, Inc . (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical...

SPRB : 80.99 (+1.25%)
Why This Microcap Biotech Stock Surged 1,378% in a Single Day

Shares of Spruce Biosciences (NASDAQ: SPRB) surged 1,378% to $130.40 on Monday after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation (BTD) to tralesinidase alfa (TA-ERT)...

SPRB : 80.99 (+1.25%)
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)

Breakthrough Therapy Designation Supported by Integrated Long-Term Clinical Data Demonstrating Normalization in Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE) ...

SPRB : 80.99 (+1.25%)
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need,...

SPRB : 80.99 (+1.25%)
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates

Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrates Profound and Durable Efficacy and Safety in Patients with Sanfilippo...

SPRB : 80.99 (+1.25%)
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)

TA-ERT Profoundly and Durably Lowered Cerebral Spinal Fluid Heparan Sulfate Non-Reducing End (CSF HS-NRE), the Factor Responsible for Neurodegeneration in MPS IIIB ...

SPRB : 80.99 (+1.25%)
Spruce Biosciences Announces Reverse Stock Split

Spruce’s Common Stock to Begin Trading on a Post-Split Adjusted Basis on August 5, 2025 Relisting on Nasdaq Capital Market Anticipated Following...

SPRB : 80.99 (+1.25%)
S&P Futures Climb Ahead of Key U.S. PPI and Retail Sales Data, Adobe Earnings on Tap

March S&P 500 E-Mini futures (ESH24) are trending up +0.37% this morning as market participants geared up for crucial U.S. PPI and retail sales data while also awaiting quarterly results from software...

PATH : 19.30 (+3.37%)
DG : 125.10 (-5.49%)
ULTA : 593.27 (-1.37%)
C : 108.05 (-0.76%)
FSR : 0.0897 (-28.13%)
DLTR : 120.49 (-1.59%)
SPRB : 80.99 (+1.25%)
DKS : 221.75 (-4.51%)
ESH24 : 5,101.67s (-1.01%)
ECV.D.DX : 18.040 (+3.14%)
TSLA : 437.69 (-3.80%)
SDF.D.DX : 11.610 (-3.01%)

Business Summary

Spruce Biosciences Inc. is a biopharmaceutical company. It focuses on developing and commercializing novel therapies for rare endocrine disorders. The company develops tildacerfont, an non-steroidal therapy which are in clinical stage. Spruce Biosciences Inc. is based in Daly City, California.

See More

Key Turning Points

3rd Resistance Point 92.66
2nd Resistance Point 89.33
1st Resistance Point 84.66
Last Price 80.99
1st Support Level 76.66
2nd Support Level 73.33
3rd Support Level 68.66

See More

52-Week High 240.00
Fibonacci 61.8% 149.95
Fibonacci 50% 122.14
Fibonacci 38.2% 94.32
Last Price 80.99
52-Week Low 4.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar